App-Quantinova.ai

SWOG S1404: A phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma.

Kenneth F. Grossmann - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Pembrolizumab

Efficacy of immunotherapy in advanced melanoma: A network meta-analysis.

Belal Firwana - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

PD-1 blockade to treat mucosal and uveal melanoma: The University of Pittsburghh experience.

Ling Tian - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Uveal melanoma

Pembrolizumab

Single-center "real life experience" with pembrolizumab (PEMBRO) in pretreated advanced melanoma patients.

Yanina Jansen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

Treatment patterns for metastatic melanoma in US community oncology clinical practice: A retrospective observational study.

Eric D. Whitman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

Correlation between baseline characteristics and clinical outcome of patients with pretreated advanced melanoma who received pembrolizumab (PEMBRO) in an expanded access program (EAP).

Elisa A. Rozeman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Pembrolizumab

Incidence and risk of pneumonitis associated with nivolumab and pembrolizumab in patients with cancer: A meta-analysis of clinical trials.

Ling Peng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pulmonary alveolar proteinosis

Pembrolizumab

Phase 1/2 study of pembrolizumab (pembro) in children with advanced melanoma or a PD-L1positive (PD-L1+) advanced, relapsed, or refractory solid tumor or lymphoma (KEYNOTE-051).

Birgit Geoerger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

KEYNOTE-119: A randomized phase III study of single-agent pembrolizumab (MK-3475) vs single-agent chemotherapy per physicians choice for metastatic triple-negative breast cancer (mTNBC).

Eric P. Winer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Pembrolizumab

Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (Pexidartinib/PLX3397) with an anti PD-1 antibody (Pembrolizumab) to treat advanced, solid tumors.

Amita Patnaik - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers.

Naiyer A. Rizvi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Jeffrey R. Infante - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Squamous cell carcinoma of the head and neck

Pembrolizumab

Phase I STORM study (KEYNOTE 200): Intravenous delivery of a novel oncolytic immunotherapy agent, Coxsackievirus A21 in combination with pembrolizumab in advanced cancer patients.

Hardev S. Pandha - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Cerebral metastases

Pembrolizumab

IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K- inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors.

Anthony W. Tolcher - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pembrolizumab

A phase I study of pembrolizumab in combination with enadenotucirev (EnAd) (SPICE) in subjects with metastatic or advanced carcinoma.

Wael A. Harb - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Salivary gland cancer

Pembrolizumab

Epigenetic priming prior to pembrolizumab in microsatellite-stable (MSS) advanced colorectal cancer.

Adrian Gerard Murphy - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

KEYNOTE-164: phase 2 study of pembrolizumab for patients with previously treated, microsatellite instability-high advanced colorectal carcinoma.

Dung T. Le - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

KEYNOTE-177: first-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator-choice chemotherapy for mismatch repairdeficient or microsatellite instabilityhigh metastatic colorectal carcinoma.

Luis A. Diaz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colorectal Cancer

Pembrolizumab

Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: phase 3 KEYNOTE-061 study.

Atsushi Ohtsu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Pembrolizumab

KEYNOTE-062: phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Josep Tabernero - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Brain metastasis

Pembrolizumab

Filters

2307 Abstracts